95 g/L in pancreatic cancer group versus 15.98 g/L in the colorectal cancer, p = 0.03). Table 3 Factors associated with high levels of adiponectin (> 10 microG/L) (univariate analysis) After analyzing the ROC curves in the PC group,

we selected as threshold a rate of adiponectin of 10 µg/L, with the best sensitivity/specificity ratio for the association between high ADP level and PC. The area under the receiver operating characteristic curve (ROC) for the highest ADP concentration was 0.81 (OR = 21.1; 95%CI = 1.4-150; p = 0.031). A specificity of 87% was seen at the cut-off level of 10 microG/L but with a sensitivity of 75%. In this study, the threshold value could be part of the EPZ-6438 supplier diagnosis of pancreatic cancer Inhibitors,research,lifescience,medical in diabetes mellitus, with a sensibility of 87%. There was no significant difference Inhibitors,research,lifescience,medical between both groups in univariate analysis for the portion of patients above this threshold (adiponectin > 10 µg/L: 69.6% vs 82.9%, p = 0.195). The HOMA indexes were comparable between the two groups. In the pancreatic cancer group, adiponectin Inhibitors,research,lifescience,medical levels were lower (less than 10 g/L) in the presence of type 2 diabetes (44.4% vs 14.6%, p = 0.013) and in the presence of insulin resistance measured by HOMA index (50.0%

vs 11.5%, p = 0.049). In multivariate analysis (Table 4) , after adjustment on sex, age (< 75 years), bilirubin (> 20 µmol/L) and weight loss (> 10%), the variables independently associated with high levels of adiponectin (> 10 µg/L) were: the presence of pancreatic cancer (OR = 12.03, p Inhibitors,research,lifescience,medical = 0.047), diabetes (OR = 0.07, p = 0.01) and the insulin resistance (OR = 0.42, p = 0.05). Table 4 Factors associated with high levels of adiponectin (> 10 microG/L) (multivariate analysis) In conclusion, adiponectin is twelve times higher (> 10 µg/L) in patients presenting with pancreatic cancer than in patients with colorectal cancer after adjustment on diabetes Inhibitors,research,lifescience,medical mellitus (Table 4). Adiponectin-Diabetes

Relationship The low number of diabetic patients in the colorectal cancer group has not allowed analysis and comparison with the group with pancreatic cancer. We therefore focused on the characterization of diabetes in patients with adenocarcinoma Endocrine Reviews of the pancreas. Diabetes was present in 21 patients (39.6%) with pancreatic cancer. It was present of PC within 3 months before diagnosis in 34% of cases and in 43.0% of cases within 3 years preceding the diagnosis of pancreatic cancer. One half of patients were men (p = 0.857). The age at the time of diagnosis of pancreatic cancer was not statistically different according to the presence or absence of diabetes. Diabetic patients under 75 years represent 59.3% of cases (p = 0.760). In univariate analysis, the presence of diabetes was associated with obesity (over-weight: 42.9% vs 18.8%, obesity: 33.3% vs 9.4%, p = 0.002), hypercholesterolemia (28.6% vs 6.3%, p = 0.037) and insulin-resistance (HOMA > 3.5 : 50.0% vs 0%, p = 0.001).